Kenvue Inc. (NYSE:KVUE) Stake Boosted by Swedbank AB

Swedbank AB lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 13.1% during the fourth quarter, Holdings Channel reports. The firm owned 890,980 shares of the company’s stock after buying an additional 103,117 shares during the period. Swedbank AB’s holdings in Kenvue were worth $19,022,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in KVUE. Valicenti Advisory Services Inc. grew its stake in Kenvue by 1.6% during the 4th quarter. Valicenti Advisory Services Inc. now owns 108,455 shares of the company’s stock worth $2,316,000 after buying an additional 1,752 shares during the last quarter. Perigon Wealth Management LLC boosted its holdings in shares of Kenvue by 19.8% during the fourth quarter. Perigon Wealth Management LLC now owns 19,249 shares of the company’s stock valued at $408,000 after acquiring an additional 3,187 shares during the period. Cornell Pochily Investment Advisors Inc. grew its position in shares of Kenvue by 17.4% during the fourth quarter. Cornell Pochily Investment Advisors Inc. now owns 10,917 shares of the company’s stock worth $233,000 after acquiring an additional 1,615 shares during the last quarter. Mount Yale Investment Advisors LLC increased its holdings in shares of Kenvue by 50.6% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 34,599 shares of the company’s stock worth $739,000 after acquiring an additional 11,632 shares during the period. Finally, Novare Capital Management LLC lifted its position in Kenvue by 6.2% in the 4th quarter. Novare Capital Management LLC now owns 491,970 shares of the company’s stock valued at $10,504,000 after purchasing an additional 28,616 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on KVUE. Bank of America upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $23.08.

Kenvue Price Performance

Shares of Kenvue stock opened at $21.29 on Friday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $40.82 billion, a PE ratio of 38.71, a price-to-earnings-growth ratio of 2.05 and a beta of 1.46. The company’s 50-day moving average price is $21.90 and its two-hundred day moving average price is $21.87.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the previous year, the company posted $0.31 EPS. The business’s revenue was down .4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.85%. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.